Denis Chem Lab Ltd
Incorporated in 1982, Denis Chem Lab Ltd does manufacturing of Pharmaceuticals Transfusion Solution in Bottles[1]
- Market Cap ₹ 99.9 Cr.
- Current Price ₹ 72.0
- High / Low ₹ 109 / 56.1
- Stock P/E 11.9
- Book Value ₹ 66.0
- Dividend Yield 2.07 %
- ROCE 14.0 %
- ROE 9.52 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.07 times its book value
- Company has been maintaining a healthy dividend payout of 32.7%
Cons
- The company has delivered a poor sales growth of 10.8% over past five years.
- Promoter holding is low: 39.0%
- Company has a low return on equity of 11.2% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 75 | 98 | 112 | 107 | 123 | 135 | 109 | 136 | 161 | 167 | 173 | 182 | |
| 66 | 89 | 98 | 95 | 110 | 120 | 99 | 122 | 142 | 146 | 157 | 164 | |
| Operating Profit | 9 | 8 | 14 | 12 | 14 | 15 | 10 | 14 | 19 | 21 | 16 | 18 |
| OPM % | 12% | 9% | 12% | 11% | 11% | 11% | 9% | 11% | 12% | 13% | 9% | 10% |
| 0 | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | |
| Interest | 5 | 7 | 6 | 5 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 6 | 7 | 6 | 6 | 7 | 6 | 6 | 8 | 7 | 7 | 7 |
| Profit before tax | 0 | -3 | 2 | 2 | 6 | 6 | 3 | 9 | 11 | 15 | 11 | 12 |
| Tax % | 78% | 30% | 37% | -5% | -7% | 26% | 27% | 30% | 28% | 26% | 27% | 29% |
| 0 | -4 | 1 | 2 | 6 | 4 | 2 | 6 | 8 | 11 | 8 | 8 | |
| EPS in Rs | 0.07 | -4.16 | 0.89 | 1.54 | 4.58 | 3.03 | 1.63 | 4.51 | 5.66 | 8.04 | 5.82 | 6.06 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 22% | 0% | 46% | 33% | 35% | 31% | 26% | 41% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 11% |
| 3 Years: | 4% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 30% |
| 3 Years: | 2% |
| TTM: | 4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 7% |
| 3 Years: | -3% |
| 1 Year: | -30% |
| Return on Equity | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 11% |
| 3 Years: | 11% |
| Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 12 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 8 | 7 | 18 | 36 | 43 | 45 | 48 | 53 | 58 | 66 | 71 | 78 |
| 48 | 44 | 37 | 25 | 23 | 14 | 9 | 3 | 2 | 1 | 1 | 4 | |
| 17 | 24 | 27 | 26 | 26 | 25 | 22 | 27 | 25 | 28 | 26 | 29 | |
| Total Liabilities | 81 | 85 | 94 | 101 | 106 | 97 | 92 | 96 | 99 | 109 | 112 | 125 |
| 42 | 40 | 44 | 40 | 50 | 46 | 41 | 42 | 35 | 38 | 39 | 37 | |
| CWIP | 0 | 10 | 1 | 5 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 39 | 35 | 49 | 56 | 55 | 52 | 51 | 55 | 62 | 72 | 73 | 88 | |
| Total Assets | 81 | 85 | 94 | 101 | 106 | 97 | 92 | 96 | 99 | 109 | 112 | 125 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14 | 21 | 7 | 11 | 8 | 13 | 8 | 17 | 16 | 18 | 12 | 4 | |
| -28 | -13 | -1 | -16 | -2 | -2 | -1 | -10 | -11 | -15 | -8 | -5 | |
| 13 | -7 | -0 | 1 | -5 | -14 | -6 | -7 | -4 | -4 | -4 | 0 | |
| Net Cash Flow | -1 | 1 | 5 | -4 | 1 | -3 | 1 | -0 | 1 | -1 | -0 | -0 |
| Free Cash Flow | -14 | 8 | 5 | 2 | -2 | 11 | 6 | 12 | 12 | 11 | 4 | -1 |
| CFO/OP | 154% | 246% | 49% | 92% | 65% | 101% | 85% | 126% | 100% | 104% | 105% | 38% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 123 | 85 | 104 | 105 | 106 | 94 | 110 | 85 | 71 | 69 | 65 | 78 |
| Inventory Days | 40 | 39 | 35 | 52 | 50 | 51 | 60 | 50 | 39 | 43 | 37 | 40 |
| Days Payable | 81 | 119 | 136 | 150 | 102 | 108 | 103 | 99 | 79 | 90 | 81 | 81 |
| Cash Conversion Cycle | 81 | 4 | 3 | 8 | 55 | 37 | 67 | 36 | 31 | 22 | 21 | 36 |
| Working Capital Days | -19 | -57 | -13 | 4 | 17 | 32 | 63 | 51 | 41 | 37 | 38 | 50 |
| ROCE % | 11% | 5% | 12% | 9% | 11% | 11% | 6% | 14% | 16% | 20% | 14% | 14% |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Debtors Turnover Days |
|
|||||||
| Installed Capacity - Eurohead Bottles Crore Bottles per annum |
||||||||
| Installed Capacity - Glass Bottles Crore Bottles per annum |
||||||||
| Installed Capacity - Plastic Bottles (BFS) Crore Bottles per annum |
||||||||
| Number of Employees Number |
||||||||
| Number of Licensed Products Number |
||||||||
| Overall Capacity Utilization % |
||||||||
Extracted by Screener AI
Documents
Announcements
- Corporate Action-Board approves Dividend 30 May
-
Announcement Under Regulation 30 Of SEBI (LODR)- Intimation Of Appointment Of Secretarial Auditor
30 May - FY26 audited results approved; final dividend Rs.2.50/share; net profit Rs.840.93 lakh, unmodified audit opinion.
-
Announcement under Regulation 30 (LODR)-Change in Management
30 May - FY26 audited results approved; final dividend Rs 2.50/share recommended; profit Rs 840.93 lakh, unmodified opinion.
- Results - Financial Results For 31St March, 2026. 30 May
-
Board Meeting Outcome for Outcome Of Board Meeting - Submission Of Audited Financial Results For The Financial Year Ended On 31St March, 2026 & Other Intimations
30 May - 30 May 2026 board approved FY26 audited results, Rs 2.50 dividend, profit Rs 840.93 lakh.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
DCLL manufactures and markets sterile Intravenous injectibles in Glass and Plastic Bottles for human and veterinary consumption. It also manufactures products on contract basis for multinational pharmaceutical companies who market them under their own brands. Company has a fully equipped in-house Quality Control Laboratory having different interdepartments for Chemical Testing, Physico-Chemical Testing, Microbiological Testing, Pyrogens Testing, Sterility Testing and Toxicity Testing. All raw materials, packaging materials, in process testing and finished stocks are tested in-house.